July 16, 2026 —
REGENXBIO announced a proposed underwritten public offering of common stock, with the company seeking to raise $100 million in gross proceeds.
The proposed financing comes as REGENXBIO advances multiple late-stage AAV gene therapy programs toward potential regulatory decisions and pivotal readouts. The company has granted underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering.
Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho are acting as joint book-running managers for the proposed offering. The final size, pricing, and completion of the offering remain subject to market conditions.
REGENXBIO did not provide a detailed use-of-proceeds breakdown in the announcement. However, the financing comes as the company continues supporting clinical, regulatory, manufacturing, and commercial readiness activities across its rare disease and retinal disease pipeline.
REGENXBIO’s most advanced program is RGX-202, an investigational AAV8 microdystrophin gene therapy for Duchenne muscular dystrophy. In May 2026, the company reported positive pivotal data, with 93% of participants achieving at least 10% microdystrophin expression at Week 12. REGENXBIO is targeting a Biologics License Application submission under the accelerated approval pathway.
The company is also advancing clemidsogene lanparvovec, also known as RGX-121 or NAVSUNLI, for Hunter syndrome, or MPS II. The program has been under FDA review, with REGENXBIO targeting a resubmission in the third quarter of 2026. Commercialization would be led by partner Nippon Shinyaku if approved.
In ophthalmology, REGENXBIO is co-developing surabgene lomparvovec, or ABBV-RGX-314, with AbbVie for wet age-related macular degeneration and diabetic retinopathy. Pivotal wet AMD data are expected in the fourth quarter of 2026. The diabetic retinopathy program recently dosed its first patient in a pivotal trial, triggering a $100 million milestone payment from AbbVie.
The proposed public offering adds another source of capital alongside REGENXBIO’s partnership economics, including milestone and collaboration payments from AbbVie and Nippon Shinyaku. The financing also reflects the broader trend of AAV-focused developers seeking additional capital as programs approach late-stage clinical and regulatory milestones.
With three late-stage gene therapy programs progressing across Duchenne muscular dystrophy, Hunter syndrome, and retinal disease, REGENXBIO is entering a critical period. The company’s ability to manage regulatory execution, safety monitoring, manufacturing readiness, and potential launch preparation will be central to whether its pipeline can translate into approved therapies.
